Sarah A. Sullivan

Sarah A. Sullivan

Counsel

Contact Info

Phone: (973) 286-6728
Fax: (973) 286-6828

Primary Office

Newark
One Riverfront Plaza
1037 Raymond Blvd., Suite 1520
Newark, NJ 07102-5426

Secondary Office

New York
1270 Avenue of the Americas
Suite 2005
New York, NY 10020

Sarah A. Sullivan

Counsel

Sarah Sullivan represents pharmaceutical companies involved in complex, high stakes patent litigation. Sarah concentrates her practice on Hatch-Waxman ANDA cases and disputes over the intellectual property behind branded pharmaceuticals. She is part of the Firm's nationally-recognized team for patent litigation and serves as New Jersey litigation counsel in patent cases for approximately 20 major pharmaceutical companies. A Lex Machina report recognized the Saul Ewing Arnstein & Lehr team in 2018 as one of the top five “Go-To” law firms for patent litigation. The team was also ranked fourth, nationally, for the number of cases filed on behalf of patentees between 2015 and 2017, and fourth, nationally, for the number of cases filed on behalf of ANDA plaintiffs between 2009 and 2017.

Sarah has also represented clients in complex commercial disputes involving contracts and intellectual property assets.  

Sarah is admitted to practice before the U.S. District Court for the District of New Jersey, the U.S. Court of Appeals for the Third Circuit, the U.S. Court of Appeals for the Federal Circuit, and the state courts of New Jersey and New York.

Experience

Indivior and Aquestive Therapeutics (Suboxone®)

Representation of Indivior Inc., Indivior UK Limited, and Aquestive Therapeutics, Inc. against Dr. Reddy’s, Alvogen, Par, and Teva in Hatch-Waxman patent litigation involving Suboxone® sublingual film brand drug product, which treats opioid dependency (annual worldwide sales totaling more than $1 billion). In these hotly-contested matters, Indivior and Aquestive were able to enjoin at-risk launches of generic product by obtaining a TRO against Alvogen and both a TRO and a Preliminary Injunction against Dr. Reddy’s, as well as defeating three post-TC Heartland transfer motions brought by Dr. Reddy’s, Alvogen, and Teva.

Celgene (Otezla®)

Representation of Celgene Corporation against Mankind, Torrent, Glenmark, MSN, Teva, Prinston, Emcure, Macleods, Aurobindo, Hetero, Cipla, Alkem, Zydus, Unichem, Dr. Reddy’s, Amneal, Pharmascience in Hatch-Waxman patent litigation involving Otezla® brand drug product, which treats moderate to severe plaque psoriasis (annual worldwide sales totaling more than $1.5 billion).

Mitsubishi Tanabe and Janssen (Invokana® and Invokamet®)

Representation of Mitsubishi Tanabe Pharma Corp., Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, Janssen Research and Development, LLC, and Cilag GmbH International against Aurobindo, Macleods, InvaGen, Prinston, Dr. Reddy’s, Hetero, Apotex, MSN, Laurus Labs, Indoco, Zydus, Sandoz, Teva, and Lupin in Hatch-Waxman patent litigation involving the Invokana® and Invokamet® brand drug products, which treat diabetes (annual sales totaling more than $1 billion).

Celgene (Pomalyst®)

Representation of Celgene Corporation against Par, Teva, Hetero, Aurobindo, Apotex, Mylan, Synthon, and Breckenridge in Hatch-Waxman patent litigation involving Pomalyst® brand drug product, which treats multiple myeloma (annual worldwide sales totaling approximately $2 billion).

Sumitomo Dainippon Pharma and Sunovion (Latuda®)

Representation of Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc. against Teva, Emcure, and InvaGen in Hatch-Waxman patent litigation involving the Latuda® brand drug product, an anti-psychotic drug, which treats schizophrenia and depression in adults with bipolar disorder (annual sales totaling approximately $1 billion). The case concluded after a favorable Markman ruling forced the defendants to concede infringement and validity of Sunovion's patent. The court’s ruling was appealed to the Federal Circuit and was affirmed in April of 2018 in favor of Sumitomo and Sunovion.

Helsinn and Roche Palo Alto (Aloxi®)

Representation of Helsinn Healthcare S.A. and Roche Palo Alto LLC against Teva and Dr. Reddy's in Hatch-Waxman patent litigation involving the Aloxi® brand drug product, an intravenous therapy for the prevention of chemotherapy-induced nausea and vomiting (annual sales totaling more than $600 million). In the case against Teva, following a 12-day bench trial, the court issued a 167-page opinion and judgment in favor of Helsinn on infringement and validity, upholding Helsinn's patents over multiple claims of obviousness and the on-sale bar provisions of the America Invents Act, which was an issue of first impression due to changes in the AIA. The trial decision was reversed on appeal at the Federal Circuit. After granting a writ of certiorari, the U.S. Supreme Court affirmed the Federal Circuit in early 2019.

Merck (Emend® IV)

Representation of Merck Sharp & Dohme Corp. in a trial victory against Sandoz Inc. in Hatch-Waxman patent litigation involving the Emend® IV brand drug product (market value of judgment in excess of $1.5 billion). Emend® IV is an intravenous therapy for the prevention of chemotherapy-induced nausea and vomiting (annual sales totaling more than $400 million). Following a bench trial that took place over the course of two weeks – and with just two days to spare before the 30-month stay expired – the court upheld the validity of Merck's compound patent, finding that its claims were valid and infringed.

Sunovion Pharmaceuticals (Lunesta®) 

Representation of Sunovion Pharmaceuticals (formerly Sepracor Inc.) against 10 generic pharmaceutical manufacturers in Hatch-Waxman patent litigation concerning the Lunesta® brand drug product, a highly successful sleep aid (annual sales totaling approximately $1 billion). The case concluded at the Federal Circuit with a precedent-setting judgment of infringement and dismissal of all inequitable-conduct defenses in favor of Sunovion. Prior to the appeal, the district court issued one of the first post-Exergen decisions dismissing a generic drug manufacturer's inequitable-conduct defense.

Jazz (Xyrem®)

Representation of Jazz Pharmaceuticals against Roxane, Amneal, Par, Ranbaxy, Watson, Sun, Wockhardt, and Lupin in Hatch-Waxman patent litigation involving the Xyrem® brand drug product, which treats cataplexy and daytime sleepiness in narcolepsy patients (annual sales totaling approximately $130 million).

Supernus (Oxtellar XR®)

Representation of Supernus Pharmaceuticals Inc. in two trial victories against Actavis and Twi Pharmaceuticals in Hatch-Waxman patent litigation involving the Oxtellar XR® brand drug product, a once-daily antiepileptic drug indicated for adjunctive therapy for the treatment of seizures in adults and in children 6 to 17 years of age (Annual sales totaling approximately $10 million). Following two separate bench trials, the court issued judgments in favor of Supernus on infringement and validity. Both trial decisions were appealed to the Federal Circuit and were affirmed in favor of Supernus.

Celgene (Revlimid®)

Representation of Celgene Corporation against Natco, Arrow, Watson, and Dr. Reddy's involving Celgene's blockbuster Revlimid® brand drug product. Revlimid® is a more potent derivative of its predecessor Thalomid® and is used to treat multiple myeloma and certain blood disorders known as myelodysplastic syndromes. Revlimid® has annual sales totaling more than $6 billion. This representation is ongoing with respect to the case against Dr. Reddy's.

Boehringer (Pradaxa®)

Representation of Boehringer Ingelheim against Teva, Alkem, Mylan, and Breckenridge in ANDA patent litigation involving the Pradaxa® brand drug product. Pradaxa® is an anticoagulant that prevents stroke and blood clots in patients who have atrial fibrillation. Annual sales of Pradaxa® total approximately $800 million. Boehringer prevailed on a motion to dismiss for lack of personal jurisdiction brought by Mylan in the wake of the Supreme Court's Daimler decision, which was an emerging issue in Hatch-Waxman litigation across the country and an issue of first impression in the District of New Jersey. This representation is ongoing.

University of Illinois (Prezista®)

Representation of the Board of Trustees of the University of Illinois against six generic pharmaceutical manufacturers in patent litigation involving the Prezista® brand drug product. Prezista® is an HIV treatment drug, and the University's patent covered a method of using Prezista® in combination with another drug to overcome patient resistance to HIV treatment. Prezista® has annual sales totaling approximately $230 million. The case concluded with a favorable settlement for the University.

Johnson & Johnson-DePuy Orthopaedics (Pinnacle® and Duraloc® Acetabular Cup Systems)

Representation of DePuy (a division of New Jersey-based Johnson & Johnson) in patent litigation against Stryker involving DePuy's Pinnacle® and Duraloc® Acetabular Cup Systems, which have annual sales totaling approximately $200 million. Following a favorable Markman ruling for DePuy, Stryker conceded its infringement suit against DePuy and moved for a judgment pursuant to Fed. R. Civ. P. 54(b). DePuy successfully defeated that motion, which eventually led to Stryker withdrawing all of its infringement claims against DePuy.

Gilead (Letairis®)

Representation of Gilead Sciences, Inc. and Royalty Pharma Collection Trust against Watson, Actavis, and Sigmapharm in patent litigation involving the Letairis® brand drug product. Letairis® is an oral drug used for the treatment of pulmonary arterial hypertension with annual sales totaling approximately $595 million. The case was settled in 2017 on terms highly favorable to Gilead.

Credentials and Accolades

Memberships and Affiliations

New Jersey State Bar Association, Young Lawyers Division

American Bar Association, Young Lawyers Division

Education

J.D., New York Law School, 2006, magna cum laude

  • Executive Notes Editor, New York Law School Law Review
  • John Marshall Harlan Scholar
  • Member, Center for Professional Values and Practice

B.A., College of the Holy Cross, 2003

  • Dean's List
  • Sigma Tau Delta
  • Editor, Holy Cross Literary Journal

Bar Admissions

New Jersey
New York

Firm Management Positions

Sarah Sullivan represents pharmaceutical companies involved in complex, high stakes patent litigation. Sarah concentrates her practice on Hatch-Waxman ANDA cases and disputes over the intellectual property behind branded pharmaceuticals. She is part of the Firm's nationally-recognized team for patent litigation and serves as New Jersey litigation counsel in patent cases for approximately 20 major pharmaceutical companies. A Lex Machina report recognized the Saul Ewing Arnstein & Lehr team in 2018 as one of the top five “Go-To” law firms for patent litigation. The team was also ranked fourth, nationally, for the number of cases filed on behalf of patentees between 2015 and 2017, and fourth, nationally, for the number of cases filed on behalf of ANDA plaintiffs between 2009 and 2017.

Sarah has also represented clients in complex commercial disputes involving contracts and intellectual property assets.  

Sarah is admitted to practice before the U.S. District Court for the District of New Jersey, the U.S. Court of Appeals for the Third Circuit, the U.S. Court of Appeals for the Federal Circuit, and the state courts of New Jersey and New York.